Article

Coming together: The ATS/ERS consensus on clinical pulmonary function testing

Università degli Studi di Genova, Genova, Liguria, Italy
European Respiratory Journal (Impact Factor: 7.13). 08/2005; 26(1):1-2. DOI: 10.1183/09031936.05.00034205
Source: PubMed
0 Followers
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This case-controlled clinical study was undertaken to investigate to what extent pulmonary function in individuals with chronic spinal cord injury (SCI) is affected by posture. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximal inspiratory pressure (PImax) and maximal expiratory pressure (PEmax) were obtained from 27 individuals with chronic motor-complete (n=13, complete group) and motor-incomplete (n=14, incomplete group) C2-T12 SCI in both seated and supine positions. Seated-to-supine changes in spirometrical (FVC and FEV1) and airway pressure (PImax and PEmax) outcome measures had different dynamics when compared in complete and incomplete groups. Patients with motor-complete SCI had tendency to increase spirometrical outcomes in supine position showing significant increase in FVC (p=.007), whereas patients in incomplete group exhibited decrease in these values with significant decreases in FEV1 (p=.002). At the same time, the airway pressure values were decreased in supine position in both groups with significant decrease in PEmax (p=.031) in complete group and significant decrease in PImax (p=.042) in incomplete group. In addition, seated-to-supine percent change of PImax was strongly correlated with neurological level of motor-complete SCI (ρ=-.77, p=.002). These results indicate that postural effects on respiratory performance in patients with SCI can depend on severity and neurological level of SCI, and that these effects differ depending on respiratory tasks. Further studies with adequate sample size are needed to investigate these effects in clinically specific groups and to study the mechanisms of such effects on specific respiratory outcome measures.
    Respiratory Physiology & Neurobiology 08/2014; DOI:10.1016/j.resp.2014.08.013 · 1.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary surfactant protein D (SP-D) is considered a candidate biomarker for lung integrity and for disease progression. In the present study, we aimed to estimate the serum levels of SP-D in patients with chronic obstructive pulmonary disease (COPD) and to assess the correlation of these biomarkers with indices of COPD severity. Subjects and methods The study was carried out on 30 COPD male patients and 15 apparently healthy age-matched males as control. COPD patients were divided by GOLD stages into 10 patients stage I–II (group 1), and 20 patients stage III–IV (group 2). A detailed history and clinical examination, pulmonary function testing by spirometry, right ventricular function assessment by conventional echocardiography and tissue Doppler imaging were done. Serum levels of total protein and albumin were determined as well as serum SP-D by enzyme-linked immunosorbent assay in both patient and control groups was determined. Results The serum level of SP-D was significantly higher in COPD patients than controls (P < 0.001). Also, these biomarkers were significantly higher in stages III and IV (group 2) compared to stages I and II (group 2) (P < 0.01). SP-D was significantly negatively correlated with serum albumin (P < 0.01) and FEV1 (P < 0.05) and not correlated with any of right ventricular function indices measured by echocardiography. Conclusion SP-D is a promising biomarker for severity in stable COPD patient. The low serum albumin could contribute to elevated serum SPD with deteriorated lung functions in stable COPD patient.
    07/2014; 63(3). DOI:10.1016/j.ejcdt.2014.03.011
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lo screening del tumore polmonare offre la possibilità di studiare le patologie indotte dal fumo di sigaretta in ampie popolazioni di studio. Il fumo di sigaretta è responsabile infatti di diversi tipi di patologie toraciche oltre al cancro, come ad esempio l’enfisema, la patologia cronica delle vie aeree, certi tipi di malattie interstiziali e la coronaropatia. Sebbene queste alterazioni siano considerate come reperti incidentali in un contesto di screening, la loro valutazione non deve essere sottostimata in quanto può fornire importanti informazioni circa la loro prevalenza, i loro meccanismi patogenetici e il loro legame con il cancro polmonare. Lung cancer screening trials offer the unique opportunity to investigate the smoking-induced pulmonary diseases on large study populations. Smoke is related to a wide spectrum of diseases other than lung cancer, such as pulmonary emphysema, airways disease, interstitial lung disease and coronary disease. Although these abnormalities are commonly regarded as incidental findings in a lung cancer screening setting, their evaluation might provide either important information on their prevalence and crucial insights for the comprehension of their pathogenesis and link with lung cancer.

Preview

Download
0 Downloads
Available from